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Evidence for delayed-type hypersensitivity mechanisms in
glomerular crescent formation
XIA0 Ru HUANG, STEPHEN R. HOLDSWORTH, and PETER G. TIPPING
Centre for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia
Evidence for delayed-type hypersensitivity mechanisms in glomerular
crescent formation. The role of CD4-positive T cells in glomerular
crescent formation was examined in WKY rats. Glomerulonephritis
(ON) was induced by a subnephntogenic intravenous dose of sheep
anti-rat GBM antibody in rats previously sensitized to sheep globulin.
This resulted in a severe proliferative and crescentic ON, with marked
proteinuria [143 40 mg/24 hr (mean SD), normal 1.6 0.7 mg/24 hr]
and crescent formation involving 59 8% of glomeruli at day 10
(normal 0%). Humoral immunity to sheep globulin was evident system-
ically by high titers of circulating anti-sheep globulin and locally by
linear deposition of rat immunoglobulin in glomeruli and cell mediated
immunity by cutaneous delayed-type hypersensitivity (DTH) to intra-
dermal injection of sheep globulin. Glomerular accumulation of CD5
positive T cells 12.45 0.21 cells per glomerular cross section (c/gcs),
normal 0.18 0.10 c/gcs], CD4 positive T cells, (1.87 0.46 c/gcs,
normal 0.14 0.08 c/gcs), and macrophages (22.7 5.9 c/gcs, normal
0.05 0.05 c/gcs), together with the appearance of multinucleated giant
cells (0.42 0.15 c/gcs, normal 0 c/gcs) suggested a DTH-like reaction
in glomeruli. Sensitized rats given anti-GBM globulin were treated with
monoclonal anti-CD5 or anti-CD4 antibodies in a protocol which
prevented cutaneous DTH to sheep globulin without altering the
humoral immune response. Both treatments significantly reduced gb-
merular accumulation of CD5 and CD4 positive T cells at day 10.
Crescent formation was significantly reduced (CD5 treated, 13 4% of
glomeruli affected; P < 0.001; CD4 treated 13 3% of glomeruli
affected, P < 0.001) compared to rats treated with an isotype-matched
irrelevant monoclonal antibody. Glomerular macrophage accumulation,
multinucleated giant cell formation and proteinuria were also signifi-
cantly reduced by both treatments. These studies demonstrate a func-
tional role for CD4 positive T cells as effector cells within glomeruli,
separate from their role in humoral immunity, in the development of
crescentic ON. The local participation of CD4 positive T cells, macro-
phages and multinucleated giant cells in crescent formation, and the
attenuation of these features by functional T helper cell depletion
suggest that local DTH-like mechanisms may contribute to glomerular
crescent formation.
Glomerular crescent formation is a feature of the most severe
forms of human glomerulonephritis (ON), and is associated
with poor prognosis for renal function. Crescents show similar
immunopathological features to delayed type hypersensitivity
(DTH)—a T helper cell-dependent response. These features
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include local accumulation of T cells and macrophages, prolif-
eration of adjacent epithelial cells, multinucleated giant cell
(MGC) formation and fibrin deposition. In human crescentic
GN, glomerular accumulation of both CD4 and CD8 positive T
cells is observed [1—3] often in the absence of deposition of
humoral immune mediators [4]. Olomerular macrophage accu-
mulation is prominent [5, 6] together with proliferation of
intrinsic glomerular cells, fibrin deposition and occasional
MGC. These pathological features suggest that immunological
mechanisms akin to DTH (involving an important local role for
CD4 positive T cells) may contribute to crescent formation.
There is now substantial evidence that T cells have the
potential to act as local effectors of acute glomerular injury in
GN. Bhan et al demonstrated that transfer of sensitized T cells
into rats with a planted glomerular antigen (heterologous anti-
GBM globulin) leads to accumulation of proliferating cells in
glomeruli [7]. Bolton et al demonstrated histological evidence of
glomerular injury in chickens after transfer of T cells sensitized
to GBM [8]. Oite et al demonstrated that rats sensitized to a T
cell hapten developed a proliferative GN and transient protein-
uria after the antigen was infused into the renal artery. This
injury occurred in the absence of glomerular antibody deposi-
tion [9].
The contribution of CD4 positive T helper cells to more
severe and delayed manifestation of gbomerular injury has not
been studied. T helper cells play an important role in both
humoral and cellular immune responses to antigens. Nude (T
cell deficient) mice fail to develop an immune response or
glomerular injury following immunization with human glomer-
ular antigens [10]. Therefore, in order to determine the local
effector role of T helper cells in the development of glomerular
injury in ON, protocols must be employed in which immune
sensitization and humoral immunity to the disease initiation
antigen are not altered.
In the current studies, the contribution of CD4 positive T
cells was studied in a crescentic model of anti-GBM antibody
initiated GN. T cell depletion was induced in the effector phase
of this disease in rats with an established immune response to
the disease initiating antigen, to assess the local contribution of
CD4 positive T cells to glomerular crescent formation. Thus,
the development of crescents was assessed in rats which had
high circulating titers of autologous antibody, but were unable
to develop cutaneous DTH to the disease initiating antigen.
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Methods
Animals
Male Wistar Kyoto (WKY) rats, 100 to 150 g in weight, were
obtained from Monash University Central Animal Services.
Induction of anti-GBM GN
Rats were pre-sensitized by injection of a total of 4 mg of
sheep globulin in 0.75 ml of Freunds Complete Adjuvant (FCA,
Commonwealth Serum Laboratories, Parkville, Victoria, Aus-
tralia) at two subcutaneous sites. Five days later, GN was
initiated by intravenous administration of sheep anti-rat GBM
globulin at a dose of 200 pg/g body weight. This globulin was
prepared by absorption with rat red blood cells and ammonium
sulphate precipitation of serum from a sheep immunized against
a particulate fraction of rat GBM as previously described [11].
At the administered dose, this antibody bound 30 pg of globulin
per gram wet weight of kidney (determined by trace labeling
studies) and did not produce proteinuria in non-sensitized rats.
Assessment of proteinuria
Rats were housed individually in cages to collect urine over
the final 24 hours of each experiment. Urinary protein concen-
trations were determined by the Bradford method [121, adapted
to a microtiter plate assay. Twenty microliters of diluted urine
were added to 150 d of Coomassie reagent (3 ml of 100 g!m1
Page blue 090; BDH Chemicals Ltd, Poole, UK) in 5% ethanol!
8.1% orthophosphoric acid). After 10 minutes, the absorbance
at 595 nm wavelength was read on a microtiter plate reader
(MR7000, Dynatech Laboratories, Chantilly, Virginia, USA)
and the protein concentrations calculated by reference to
bovine serum albumin (BSA; Sigma Chemical Co., St. Louis,
Missouri, USA) standards. All samples and standard were
assayed in duplicate. The 24-hour urinary protein excretion was
calculated from the 24-hour urine volume and the urinary
protein concentration.
Measurement of serum creatinine and creatinine clearance
Serum and urine creatinine concentrations were measured by
the alkaline picryc acid method using an autoanalyzer (Cobas
Bio, Roche Diagnostics, Base!, Switzerland). Creatinine clear-
ance was calculated from the serum and urine creatinine and the
urine volume.
Assessment of glomerular crescents and MGC
Kidney tissue was fixed in Bouins fixative and 2 jim tissue
sections were stained with periodic acid Schiff (PAS) reagent to
assess light microscopic appearances. Glomerular crescent
formation was assessed in a blinded protocol by counting
glomeruli with crescents in a minimum of 20 glomeruli per
animal. The presence of fibrinous material and/or cells in
Bowman's space was considered as a crescent. Crescents
ranged in extent from approximately one quarter to greater than
three quarters of the glomerular circumference. Only glomeruli
cut in equatorial cross section were scored. The percentage of
glomeruli demonstrating crescent formation was calculated
individually for each animal.
MGC were also assessed histologically in a blinded protocol.
Large multinucleated cells with > 2 nuclei were counted in a
minimum of 20 equatorially sectioned glomeruli per animal, and
the results expressed as cells per glomerular cross section
(c/gcs).
Im,nunohistological assessment of glomerular cell
accumulation
Spleen and kidney tissue from each animal was fixed in
periodate lysine paraformaldehyde for four hours, washed in
7% sucrose solution then frozen in liquid nitrogen cooled
isopentane and 4 jim sections cut on a cryostat. Tissue sections
were stained using a three layer immunoperoxidase technique
to demonstrate T cells, T cell subsets and macrophages and
natural killer (NK cells) in glomeruli. The primary antibodies
were: 0X19 (anti-CD5) as a pan T cell marker [13]; R73
[anti-a!/3T cell receptor (TCR); Serotec, Oxford, UK] [14]
W3!25 (anti-CD4) as a T helper cell marker [15]; OX8 (anti-CD8)
as a T cytotoxic/suppressor marker [15], ED-! as a macrophage
marker [16] (Serotec); and the monoclonal mouse anti-rat NK
cell marker 3.2.3 was used to detect NK cells [17] (gift of Dr. J.
Hiserodt, Pittsburgh, Pennsylvania, USA). The second anti-
body layer was a rabbit anti-mouse IgG globulin (Dako, Glos-
trup, Denmark) at a concentration of 1 in 100. This was
followed by soluble complexes of horseradish peroxidase and
mouse monoclonal anti-horseradish peroxidase immunoglobu-
lin (Dako) at a concentration of 1:100. Sections were then
incubated with diamino benzadine (Sigma), and counterstained
with Harris hematoxylin. Sections of spleen provided a positive
control for each animal, and protein 0 purified mouse globulin
was substituted for specific monoclonal antibody to provide a
negative control. Glomerular cell numbers were assessed using
a blinded protocol. A minimum of 20 equatorially sectioned
glomeruli per animal were assessed per animal and the results
were expressed as cells per glomerular cross section (c/gcs).
The coefficient of variation for mean glomerular T cell counts
on separately processed sections from an individual rat as-
sessed by the same observer was 8.5% for 0X19, 6.1% for R73,
5.0% for W3/25 and 2.5% for 0X8.
Measurement of circulating T cells and subsets
Rats were bled under ether anesthesia from the retro-orbital
venous plexus to obtain 500 to 800 jil of blood into EDTA
anticoagulant. Red blood cells were lysed in 0.1% formic acid
and the leukocyte populations analyzed by fluorescence-acti-
vated cell sorting (FACS, EPICS 752, Coulter Electronics,
Hialeah, Florida, USA) after staining with monoclonal anti-rat
T cell antibodies 0X19, R73, W3/25 and 0X8, followed by
Fat,'2 sheep anti-mouse Ig FITC (Silenus Laboratories, Mel-
bourne, Australia). Total leukocytes were detected using OX-I
(a common leukocyte antigen marker) and an irrelevant isotype-
matched monoclonal antibody was used as a negative control.
The percentage of circulating NK cells was compared in normal
WKY and Sprague-Dawley rats (N = 6 in each group), using
FACS analysis with the NK cell marker (3.2.3). The percentage
lymphocytes staining with the NK cell marker was 8.7 5.1
(mean SD) in Sprague-Dawley and 1.6 0.5 in WKY rats.
Measurement of circulating rat anti-sheep globulin antibody
Titers of rat anti-sheep globulin antibody were determined by
ELISA on serum collected at the end of each experiment.
Round-bottom polyvinylchloride microtiter plates (Dynatech)
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were coated with 1.0 g/ml normal sheep globulin in carbonate!
bicarbonate buffer pH 9.5 by incubation overnight at 4°C, and
then blocked with 2% BSA. The plates were washed twice in
phosphate buffered saline (PBS)/0. 1% Tween 20 prior to incu-
bation with serial dilutions of rat serum. After a further three
washes in PBS!Tween, plates were incubated with horseradish
peroxidase conjugated rabbit anti-rat IgG (Sigma) at a dilution
of 1 in 4000. The plates were finally washed six times with
PBSITween and incubated with 0.1 M 2,2'-azino-di-3-ethylbenz-
thiazoline suiphonate (ABTS, Boehringer Mannheim, Sydney,
Australia) in 0.02% H202. The substrate reaction was stopped
by adding an equal volume of 0.1 m citric acid!0.01% sodium
azide and the absorbance at 405 nm was read on a microtiter
plate reader (Dynatech). Serum from each rat was tested at
doubling dilutions, starting from a dilution of 1 in 10, and serum
from six non-immunized rats was tested to provide normal
controls.
Measurement of serum complement
Circulating C3 was measured by ELISA, in round bottom
microtiter plates coated with goat anti-rat C3 IgG (Nordic
Laboratories, Tilburg, The Netherlands) at a concentration of
10 g!ml. The detecting antibody was rabbit anti-rat C3 serum
(Bethyl Laboratories, Montgomery, Texas, USA) at a dilution
of I in 1000. Both these antibodies produce a single precipitin
arc against C3 in rat serum by immunoelectrophoresis. The
indicator system consisted of horseradish peroxidase-conju-
gated swine anti-rabbit IgG (Dakoplatts) at 1 in 2000, followed
by 0.01 M ABTS as described above. Serum (100 jd) from
normal, treated and control rats was assayed in duplicate at
dilutions from 1 in 100 to 1 in 10,000 and produced parallel
curves of absorbance (405 nm) versus serum dilution. The
absorbance values at a dilution of 1 in 1000 were used to
compare circulating C3 levels between groups.
Assessment of cutaneous delayed type hypersensitivity (DTH)
to sheep globulin
Rats were shaved over an area of the back and the skinfold
thickness was measured using skinfold calipers, with an accu-
racy of 0.1 mm. Rats were then injected intradermally with 100
jig of sheep globulin in 100 pA of PBS, 24 hours prior to the end
of each experiment. As a control, each rat also received a
similar intradermal injection of horse globulin. At the end of the
experiment, skinfold thickness was measured at the site of
challenge and skin lesions excised for histological examination
in representative animals.
Histologically, lesions at sites injected with sheep globulin
showed typical features of DTH reactions with tissue edema,
some fibrinoid material, and a dense mononuclear cell infiltrate
consisting mainly of CD5 and CD4 bearing lymphocytes and
ED-i positive macrophages. Some CD8 positive lymphocytes
were observed. Their time course of development was charac-
teristic of DTH. Neutrophils were evident in the lesions;
however, hemorrhagic necrosis typical of an Arthus reaction
was not observed. Skin swelling increased progressively over
the 24 hours from injection of antigen, and the increase in
skinfold thickness (in mm) was used as an index of the antigen
specific cutaneous DTH response.
Assessment of glomerular antibody deposition
Kidney tissue was frozen in liquid nitrogen cooled isopentane
for immunofluorescence microscopy. Cryostat cut tissue sec-
tions, 4 jim thickness, were stained with serial dilutions of
FITC conjugated rabbit anti-rat IgG (Silenus) starting at 1 in
100, to assess the glomerular deposition of rat IgG.
Glomerular deposition of autologous rat antibody was also
assessed quantitatively using an 1251 labeled anti-rat immuno-
globulin antibody binding assay. A normal rat was given sheep
anti-rat GBM antibody (200 jig/g body wt, i.v.) and killed 24
hours later. Glomeruli were isolated by graded sieving and
incubated in aliquots of 2000 glomeruli in 100 pA of PBS with
varying amounts of 125j labeled rat anti-sheep immunoglobulin
antibody from 5 to 200 jig, for four hours. The glomeruli were
then washed five times in PBS at 4°C and the glomerular bound
125J activity counted in a gamma-counter (LKB Wallac, Turku,
Finland). The specific amount of rat antibody bound at each
incubation concentration was then calculated from the known
specific activity of the anti-rat immunoglobulin antibody.
Incubations with the same batch of glomeruli were performed
in parallel under identical conditions using unlabeled rat anti-
sheep immunoglobulin antibody. These were washed in the
same manner to produce glomeruli with known amounts of
unlabeled, bound rat antibody. These glomeruli were then used
as standards in a binding assay using 125J labeled rabbit anti-rat
immunoglobulin antibody (Nordic Laboratories) to determine
the amount of antibody bound in glomeruli isolated from rats on
day 10 of the experimental protocol. Glomeruli from experi-
mental rats were isolated in the same manner and in parallel
with "standard" glomeruli were incubated with 125j labeled
rabbit anti-rat immunoglobulin antibody and washed exten-
sively as described above. The glomerular bound 1251 activity
was counted and a curve of bound I25J rabbit antibody versus
glomerular bound rat antibody was plotted, using the counts
from the "standard" glomeruli. This curve showed a linear
relationship for the range of glomerular bound rat antibody from
0.506 to 9.55 jsg!2 x i03 glomeruli (linear correlation coefficient,
r2 = 0.924). The amount of rat antibody in glomeruli from each
experimental rat was then calculated from the bound 1251 counts
by reference to the standard curve.
T helper cell depletion protocols
T cell depletion was induced by a single intravenous injection
of 5 mg of protein G purified mouse monoclonal antibody. Two
monoclonal antibodies were used: 0X19 (anti-CD5) [13] which
depletes both T helper and suppressor cells, and W3!25 (anti-
CD4) which inhibits CD4 positive T helper cell activation in
vitro [18] and prevents immunological injury requiring T helper
cells in vivo [19—22]. An irrelevant isotype matched (IgG1)
mouse monoclonal antibody (with specificity for human milk fat
globulin) was used as a control. Antibodies were administered
24 hours after injection of anti-GBM globulin. The extent of T
cell depletion was assessed by FACS analysis of blood on days
5 and 10 of the experimental protocol and also by staining
spleen sections from each rat obtained on day 10.
As CD4 may be expressed on resident peritoneal macro-
phages [23] and some tissue macrophages [24], the effect of
anti-CD4 antibody on glomerular macrophages was assessed in
a model of anti-GBM GN induced in naive rats. High titer
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autologous rat anti-sheep globulin (30 mg total in 3 divided
doses) was administered over 16 hours to WKY rats (N = 6)
pretreated with a subnephritogenic dose of sheep anti-rat GBM
globulin six hours earlier. Significant proteinuria developed
over the subsequent 24 hours [7.2 3.4 mg/24 h (mean SD),
control 1.8 1.5 mg124 hr, P < 0.01]. Histological examination
showed glomerular macrophage accumulation (ED I positive
cells 7.3 1.5 c/gcs) in the absence of T cells (0X19 positive
cells 0.15 0.12 c/gcs). Rats given non-immune rat globulin
instead of rat anti-sheep globulin did not develop proteinuria
(1.8 0.3 mg124 hr, or glomerular macrophage accumulation
(0.20 0.07 c/gcs). Treatment of rats with monoclonal antibody
W3/25 (5 mg, i.v.; N = 6), 24 hours prior to initiation anti-GBM
GN, did not reduce the subsequent proteinuria (10.0 5.9
mg/24 hr) or the glomerular accumulation of macrophages (ED I
positive cells 6.7 1.2 c/gcs), indicating that this antibody does
not inhibit glomerular macrophage accumulation or develop-
ment of glomerular injury in the absence of T cell participation.
Experimental design
Anti-GBM GN was induced as previously described. Deple-
tion protocols were commenced 24 hours after administration of
anti-GBM globulin and immune responses, proteinuria and
histological appearances were assessed 10 days after anti-GBM
globulin.
The following groups of rats were studied: (1.) normal rats (N
6); (2.) untreated rats with anti-GBM GN (N = 6); (3.) rats
with anti-GBM GN, treated with an isotype-matched irrelevant
monoclonal antibody (N = 8); (4.) rats with anti-GBM GN,
treated with anti-CD5 antibody (N 8); and (5.) rats with
anti-GBM GN, treated with anti-CD4 antibody (N 7).
Results are expressed as the mean standard deviation of
the mean (SD). Statistical significance was analysed by the
Mann Whitney U test.
Results
Crescentic anti-GBM GN
Untreated rats developed a severe proliferative, crescentic
GN, with prominent mononuclear cell infiltration on day 10
(Fig. 1A). This was associated with significant proteinuria [143
40 mg124 hr (mean SD, range 78 to 196); normal, 1.6 0.7
mg124 hr (range 0.3 to 1.94)], a rise in serum creatinine (167
5 tM/liter; normal, 38 10 /LM/liter; P < 0.001) and fall in
creatinine clearance (0.040 0.005 mi/mm; normal 0.64 0.03
mI/mm, P < 0.001). Crescent formation was observed in 59
8% of glomeruli (normal 0%) together with the appearance of
MGC (0.42 0.15 c/gcs, normal 0). Infiltration of both macro-
phages and T cells contributed to glomerular hypercellularity.
Glomerular macrophage numbers were markedly increased
(22.7 5.9 c/gcs) compared to normal (0.05 0.05 c/gcs, P <
0.005; Fig. 1B). A significant T cell infiltrate was also apparent
(CD5 positive T cells, 2.45 0.21 c/gcs, normal 0.18 0.10
c/gcs, P < 0.005; CD4 positive T cells 1.87 0.46 c/gcs, normal
0.14 0.08 c/gcs, P < 0.005; CD8 positive T cells, 1.05 0.30
c/gcs, normal 0.24 0.12 c/gcs, P < 0.005). Occasional NK
cells were observed in nephritic glomeruli (0.050 0.065 c/gcs)
which were not observed in normal glomeruli (0 c/gcs) (Fig. 1
C-F).
Effects of antibody treatment on circulating and splenic
lymphocytes
Following treatment with OX-19, rats with anti-GBM GN on
day 10 demonstrated markedly reduced staining of CD5, TCR,
CD4 and CD8 positive cells in splenic tissue compared to
normal rat spleen or splenic tissue from rats treated with
isotype control antibody. Staining for macrophages with ED-i
was unaltered. Rats with anti-GBM GN, treated with W3/25,
demonstrated only minor reductions in CD5, TCR and CD4
positive cells in splenic tissue on day 10. CD8 positive cells and
macrophages were unaffected.
OX-l9 treatment significantly depleted circulating T cells in
rats with anti-GBM GN. Prior to treatment 42 10% of
circulating leukocytes (Ox-i positive cells) expressed CD5 and
37 9% of cells expressed TCR. On day 5, CD5 positive cells
were reduced to 3.1 2.9% and TCR positive cells to 4.1
3.4%. On day 10, CD5 positive cells were 5.1 4.0% and TCR
positive cells to 7.9 4.0%. Treatment with W3/25 produced
only minor reduction in circulating T cells (day 5, CD5 positive
cells 27 1%, TCR positive cells 30 5%, day 10 CD5 positive
cells 23 15%, TCR positive cells 22 5%). FACS profiles of
CD5, TCR, CD4 and CD8 expression on circulating lympho-
cytes in isotype control, OX-19 and W3/25 treated rats on day
10 are shown in Figure 2.
Effect of T cell depletion of the immune response to sheep
globulin
Effect of humoral immunity. Rats developing anti-GBM GN
demonstrated high serum titers of rat anti-sheep antibody and
linear deposition of rat globulin along the GBM. Treatment with
either anti-CD5 or anti-CD4 antibodies after prior sensitization
did not affect the circulating titers of rat anti-sheep globulin
antibody. Serum from OX-19, W3/25 or isotype control anti-
body treated rats showed identical curves for the sheep globulin
binding capacity over a wide range of dilutions (Fig. 3). The
deposition of rat immunoglobulin in glomeruli was unaffected
by T cell depletion. The end-point titers for detecting rat
immunoglobulin by immunofluorescence was the same in
treated and control groups. Quantitative analysis using the
antibody binding assay demonstrated no difference in glomeru-
lar bound rat immunoglobulin in treated or control rats (isotype
control treated, 5.40 2.14 g/2 X l0 gloms; anti-CD5 treated,
6.16 3.21 g/2 x l0 gloms; anti-CD4 treated, 6.42 2.99
g/2 X i0 gloms).
Effect on T cell-mediated immune responses. Isotype control
monoclonal antibody treated rats with anti-GBM GN demon-
strated antigen specific cutaneous DTH to sheep globulin (Fig.
4). Skinfold thickness was 2.90 0.28 mm at the site of sheep
globulin injection compared to 1.40 0.11 mm for horse
globulin (P < 0.001). Normal skin thickness was 1.48 0.16
mm. Treatment with either anti-CD5 or anti-CD4 antibody
abolished cutaneous DTH reactions to sheep globulin (anti-CD5
treated 1.64 0.21 mm; anti-CD4 treated 1.47 0.60 mm).
Effect of T cell depletion on serum C3 levels
Serum C3 levels were higher in rats developing anti-GBM GN
than in normal rats. There were no differences in the serum C3
levels in treated or isotype control treated rats. At a serum
dilution of 1 in 1000, serum C3 in normal rats was 1.07 0.05
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Fig. 1. Photomicrographs ofglomeruli from a rat developing anti-GBM GN, illustrating :1w immunopathologkal features of crescentic GN on
day 10. A proliferative (iN with prominent crescent formation and MGC was present in the majority of glomeruh (A, PAS stain), associated with
prominent glomerular macrophage accumulation (B, immunoperoxidase using ED-I), and CD5, CD4 and CD8 positive cells in glomeruli, (C,
immunoperoxidase using OX-l9 D, immunoperoxidase using W3125; E, immunoperoxidase using OX-8 respectively; positive intraglomerular
cells indicated by arrows). NH cells (F, immunoperoxidase using monoelonal antibody 3.23 demonstrating a positive cell in a glomerulus) were
occasionally observed but not increased over thc numbers observed in normal glomcruli (magnification x 400 in each case).
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Both anti-CD5 and anti-CD4 treatment significantly attenu-
ated histological evidence of glomerular injury (Fig. 5) and
preserved renal function. Glomerular crescent formation, the
appearance of MGC, macrophage infiltration and proteinuria
were significantly reduced compared to isotype control treated
rats (Fig. 6). In anti-CDS treated rats, crescent formation
occurred in 13 4% of glomeruli (isotype control, 64 10% of
.-.-.--—- glomeruli, P <0.001), MGC were reduced to 0.06 0.03 c/gcs40 20 10 (isotype control, 0.40 0.11 c/gcs, P <0.001), and macrophage
infiltration to 7.1 1.9 c/gcs (isotype control 24.1 6.2 c/gcs,
P < 0.001). Proteinuria was significantly reduced [61 27
mg124 hr (range 19.8 to 95.2); isotype control 130 34 mg/24 hr
(range 82.4 to 177); P < 0.005], the rise in serum creatinine was
significantly attenuated (54 15 j.tM/liter; isotype control 167
5.2 xM/liter; P < 0.001) and the creatinine clearance was
significantly higher (0.48 0.13 mllmin; isotype control 0.04
0.01 mllmin, P < 0.001). This was associated with reduction of
CD5, TCR and CD4 positive cells in glomeruli (CD5 positive
cells 0.57 0.26 c/gcs, isotype control 2.41 0.63 c/gcs; P <
0.001; TCR positive cells 0.52 0.22 c/gcs, isotype control 2.08
A Isotype control antibody B Anti-CD5 antibody C Anti-CD4 antibody
L()
0
0
0
00L. .. I,,,I I I I I I I
50 100 150 200 I I I I I I I I —50 100 150 200
Fig. 2. FAGS profiles showing fluorescence intensity (horizontal axis) of CD5 (OX-19), a//3TCR (R73), CD4 (W3/25) and CD8 (OX-8) verses
frequency on circulating leukocytes of rats treated with isotype control antibody, OX-19 or W3/25 on day 10 of anti-GBM GN.
Effect ofT cell depletion on anti-GBM GN
I I I I
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00
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0 102405120 2560 1280 640 320 160 80
Dilution of serum, lix
Fig. 3. Rat anti-sheep globulin antibody demonstrated by ELISA on
serial serum dilutions from rats developing anti-GBM GN treated with
isotype control antibody (dots), anti-GD5 antibody (squares) and anti-
GD4 antibody (triangles). Titration of normal rat serum is also shown
(open circles).
arbitary units/100 /.Li (au) compared to 1.37 0.06 au in isotype
control treated rats with anti-GBM GN and 1.39 0.19 and 1.40
0.26 ajx in anti-CDS and anti-CD4 treated rats, respectively.
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Fig. 4. Effect of anti-CD5 and anti-CD4
antibody treatment on cutaneous DTH
responses to the disease initiating antigen
(sheep globulin) in rats developing anti -GBM
on day 10. The response to an irrelevant
antigen (horse globulin) in sensitized rats
treated with isotype control antibody and to
sheep globulin in non-sensitized rats is also
shown. The shaded areas represents average
skinfold thickness on the back of normal
WKY rats.
0.43 c/gcs; P <0.001; CD4 positive cells 0.54 0.16 c/gcs,
isotype control 1.74 0.27 c/gcs; P <0.001). CD8 positive cells
in glomeruli increased (2.47 0.78 c/gcs, isotype control 1.18
0.46 c/gcs; P <0.005; (Fig. 7). NK cells numbers (0.03 1 0.037
c/gcs) were no different from isotype control treated rats (0.050
0.065 c/gcs) (Table 1).
In anti-CD4 treated rats, crescent formation (13 3% of
glomeruli), appearance of MGC (0.04 0.01 c/gcs) and macro-
phage infiltration (5.9 1.1 c/gcs, P < 0.005) were also
significantly reduced compared to isotype treated controls (P <
0005; Fig. 6). Proteinuria [68 23 mg124 hr (range 43.7 to 94.0),
P < 0.005] and serum creatinine (51 10 sM/liter, P < 0.001)
were significantly reduced and creatinine clearance (0.43 0.09
mllmin, P < 0.001) was significantly higher. CD5 positive cells
(0.59 0.23 c/gcs), TCR positive cells (0.48 0.21 c/gcs) and
CD4 positive cells (0.54 0.19 c/gcs) in glomeruli were also
significantly depleted (P < 0.005), whereas OX-8 positive cells
were increased in number (2.82 1.00 c/gcs, P < 0.005). NK
cell numbers (0.029 0.049 c/gcs) were the same as in isotype
treated control rats (Table 1).
Discussion
The immunopathological features of crescentic GN show
marked similarities to DTH reactions which are dependent on T
helper cells. A role for sensitized T cells has been demonstrated
in recruitment of proliferating cells in glomeruli [7] and devel-
opment of transient proteinuria in rats [9]. Lymphokine produc-
tion by glomerular T cells has also been demonstrated [25] and
T cells sensitized to GBM can transfer proliferative GN in
chickens [81. These studies provide evidence for the capacity of
T cells to induce glomerular injury in GN; however, the local
contribution of T helper cells to glomerular crescent formation
via DTH-like mechanisms has not previously been studied.
Prominent crescent formation developed in response to a
planted glomerular antigen (sheep anti-rat GBM globulin) in
WKY rats presensitized by intradermal presentation of this
antigen in FCA. This presensitization resulted in a pronounced
humoral and cellular immune response to sheep globulin. These
were quantitated by measurement of serum titers of rat anti-
sheep globulin, and by skin swelling in response to intradermal
antigen challenge. The participation of effectors of humoral and
cellular immunity in glomeruli of rats developing crescentic GN
was also demonstrated by the linear deposition of rat immuno-
globulin along the GBM, and the glomerular localization of CD4
positive T cells. Other features of this crescentic model of GN
which suggested DTH-like cell-mediated immunity were the
predominance of CD4 positive T cells over CD8 positive T
cells, accumulation of macrophages and the development of
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Fig. 7. A photomicrograph of a glomerulus of a rat with anti-GBM GN
on day 10 treated with anti-CD5 antibody, demonstrating increased
number of CD8 positive cells in glomeruli (compare with Figure IE).
(Immunoperoxidase, magnification x 400).
Fig. 5. Photomicrographs of glomeruli from rats treated with isotype
control antibody (A), anti-CDS antibody (B) and anti-CD4 antibody (C)
demonstrating the histological features of GN (PAS, magnification x
400).
MGC. Previous studies have suggested that the increased
susceptibility of WKY rats to severe glomerular injury and
crescent formation is due to increased NK cell activity [26].
However, in the current study NK cells were not prominent in
crescentic glomeruli, and the percentage of circulating NK cells
in WKY rats was low compared to Sprague-Dawley rats, which
are less susceptible to crescentic GN.
The role of T helper cells as local effectors of glomerular
injury and crescent formation was assessed by in vivo func-
tional depletion using monoclonal antibodies. Rats were immu-
nized to sheep globulin and allowed to develop high titers of
specific antibody and sensitized T cells. An immune response
was then initiated in the glomerulus by planting this antigen on
the GBM, prior to blocking T cell effector functions. Measure-
ment of circulating rat anti-sheep globulin and glomerular
bound rat immunoglobulin nine days later confirmed that this
protocol did not alter the humoral immune response to the
disease initiating antigen. Circulating C3 levels were also unaf-
fected.
Treatment with OX-19 effectively depleted CD5 positive T
cells in the circulation and the spleen. This antibody does not
bind significantly to B cells [13], and has previously been
reported to produce prolonged depletion of CDS positive T cells
after a single intravenous dose [19]. Staining with a second T
cell marker (TCR) indicated that this was not merely due to
down-regulation of CD5 antigen expression. Treatment with
W3125 produced minimal depletion CD4 positive T cells. Rats
developed DTH skin lesions over the typical time coarse and
with characteristic immunohistological features, after re-chal-
lenge with the sensitizing antigen. The absence of cutaneous
DTH after intradermal challenge in rats treated with OX- 19 and
W3/25 confirmed that both treatments produced functional
ablation of CD4-dependent cellular immune responses, consis-
tent with previous reports of the functional efficacy of in vivo
treatment with these antibodies [19—221. Potential therapeutic
uses of anti-CD4 antibodies have recently been reviewed [27].
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Both treatments significantly attenuated but did not abolish
glomerular crescent formation. This effect was associated with
reduction in the appearance of CDS and CD4 positive T cells in
glomeruli, fewer giant cells and reduction of proteinuria. As
W3/25 is not an efficient depleting antibody, it may be antici-
pated that resident CD4 lymphocytes recruited to an inflamma-
tory focus as the result of a functional immunologically stimu-
lated response. Their greater reduction in glomeruli of treated
rats in comparison to the spleen and circulation was consistent
with this prediction.
Local T cell-dependent recruitment of macrophages is a
typical feature of DTH. Both anti-CD5 and anti-CD4 treatments
functionally blocked DTH and reduced glomerular macrophage
Cell type
Treatment group
Isotype control Anti-CD5 Anti-CD4
c/gcs antibody antibody antibody
CD5 positive cells 2.41 0.63 0.57 0.26 0.59 0.23
TCR positive cells 2.08 0.43 0.52 0.22 0.48 0.21
CD4 positive cells 1.74 0.27 0.54 0.16 0.54 0.19
CD8 positive cells 1.18 0.46 2.47 0.78 2.82 1.00
NK cells 0.050 0.065 0.031 0.037 0.029 0.049
________
recruitment and crescent formation, suggesting that these ef-
fects are T helper cell dependent. Their failure to completely
abrogate macrophage recruitment and crescent formation sug-
gests that other immune mediators such as immunoglobulin also
contribute to these manifestations of glomerular injury. Depo-
sition of autologous antibody along the GBM has been demon-
strated to recruit macrophages and cause glomerular injury by
Fc dependent mechanisms [28].
The potential for CD8 positive cells (T cells or NK cells) to
contribute to glomerular injury has also recently been demon-
strated in a similar non-pre-immunized anti-GBM GN model in
WKY rats [29]. In that study, CD8 cell depletion was induced
prior to antigen sensitization, allowing possible effects via
___________
alterations in antigen recognition and T and B cell sensitization
as well as the effector phase of the immune response. In the
current studies, T cell depletion was induced after antigen
sensitization to explore only the local effector role of T helper
cells. CD8 positive cells increased in glomeruli after treatment
with anti-CD5 and anti-CD4 antibodies in association with
reduced macrophage recruitment and injury, indicating that
CD8 positive cells alone do not recruit macrophages or directly
cause injury. These cells did not stain with specific anti-rat NK
cell monoclonal antibody, suggesting that they are not NK
Anti-CD4 cells. The explanation for increased numbers of CD8 bearing
antibody cells after treatment with these monoclonal antibodies is not
apparent.
In addition to T helper cells, peritoneal macrophages and
resident tissue macrophages also have the capacity to express
CD4 [15, 23], although the functional role of CD4 on macro-
phages is unknown. Some macrophage populations in the rat
are stained by the monoclonal antibody W3/25 [23]. In the
current studies, large numbers of macrophages were present in
glomeruli; however, CD4 bearing cells were relatively few in
number, indicating that at least the majority of macrophages
recruited to glomeruli in this model were not CD4 positive. The
effect of anti-CD4 antibody on macrophage function was stud-
ied in a model of GN induced by passive transfer of antibody
which results in glomerular macrophage recruitment and injury
in the absence of T cell sensitization. In this model anti-CD4
antibody treatment did not affect glomerular macrophage re-
cruitment or injury, suggesting that binding of anti-CD4 anti-
body to macrophages is not functionally significant in this
situation. In addition, CD5 is not expressed on macrophages,
but in vivo treatment with anti-CD5 antibody blocked cutaneous
DTH and glomerular injury to a similar extent to anti-CD4
treatment. These observations suggest that anti-CD4 treatment
does not significantly affect macrophage function, and the
Table 1. Effect of I cell depletion on T cells, I cell subsets, and NK
cells in glomeruli of rats developing anti-GBM GN on day 10
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Fig. 6. Effect of isotype control antibody, anti-CD5 antibody and
anti-CD4 antibody treatment on glomerular crescent formation, pro-
teinuria, macrophage recruitment and MGC formation on day 10 in rats
developing anti-GBM GN.
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inhibition of T helper cell effector functions produced by these
antibodies explains their capacity to inhibit crescent formation.
In conclusion, these studies demonstrate in vivo treatment
with monoclonal antibodies which inhibit T helper cell effector
functions attenuate or delay development of glomerular cres-
cent formation and immunopathological features suggestive of
DTH. The reduction of glomerular macrophages by both anti-
CD5 and anti-CD4 treatment suggests an important role to T
helper cells in macrophage recruitment. These effects were not
explained by alterations in the humoral immune response to the
disease initiating antigen. The observation that neither macro-
phage recruitment nor crescent formation could be completely
abolished by functional T helper cell depletion suggests that
glomerular antibody deposition (or other immunological mech-
anisms) also contributes to these features of anti-GBM GN.
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